Skip to main content
RENALYTIX PLC logo

RENALYTIX PLC — Investor Relations & Filings

Ticker · RENX ISIN · GB00BYWL4Y04 LEI · 213800NTOH3FK3WER551 IL Human health and social work activities
Open in API
Filings indexed 445 across all filing types
Latest filing 2023-11-17 Report Publication Anno…
Country GB United Kingdom
Listing IL RENX

About RENALYTIX PLC

https://renalytix.com/

Renalytix is a diagnostics company that develops artificial intelligence-enabled solutions for the clinical management of kidney disease. Its flagship product, KidneyIntelX.dkd™, is an FDA-authorized blood test for adults with type 2 diabetes and early-stage chronic kidney disease. The test utilizes a proprietary bioprognostic™ methodology to analyze biomarkers and clinical data, predicting the risk of a progressive decline in kidney function over a five-year period. This risk assessment enables clinicians to identify high-risk patients and implement targeted, guideline-recommended treatments to slow disease progression and improve outcomes.

Recent filings

Filing Released Lang Actions
Publication of Annual Report 2023 & Notice of AGM
Report Publication Announcement Classification · 100% confidence The document is a short announcement (4107 characters) released via RNS (London Stock Exchange news service). The title explicitly states: "Publication of Annual Report 2023 and Notice of 2023 Annual General Meeting". According to Rule 2, when a document is short and announces that a full report (like the Annual Report) or meeting notice has been published and provides links to where they can be found, it should be classified as a Report Publication Announcement (RPA). It is not the Annual Report (10-K) itself, nor is it the AGM material (AGM-R), but the announcement of their publication.
2023-11-17 English
Renalytix Reports Financial Results for Q1 FY2024
Interim / Quarterly Report Classification · 100% confidence The document is a press release titled 'Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024'. It contains key financial highlights, management commentary, and unaudited consolidated financial statements (Statements of Operations and Balance Sheets) for the period ended September 30, 2023. Since it provides substantive financial data for a quarterly period, it is classified as an Interim/Quarterly Report (IR). Q1 2024
2023-11-14 English
Notice of Results
Report Publication Announcement Classification · 99% confidence The document is a short announcement (3788 characters) released via RNS (RNS Number: 5522S) from Renalytix plc. The core content states that the company "will report its first quarter fiscal year 2024 financial results on Tuesday, November 14, 2023" and provides details for the subsequent conference call and webcast. This structure—announcing the future release of financial results and scheduling a call—perfectly matches the definition of a Report Publication Announcement (RPA). It is not the actual Earnings Release (ER) or the Interim Report (IR) itself, but the notice about their upcoming publication, adhering to the 'MENU VS MEAL' rule.
2023-11-07 English
Announcement of AGM and Publication of AR
Report Publication Announcement Classification · 100% confidence The document is a short announcement (3594 characters) released via RNS (RNS Number: 7470R) on October 30, 2023. The title explicitly states: "Announcement of AGM and Publication of Annual Report 2023". It informs the reader that the AGM details are set and, crucially, that the 'Annual Report for the year ended 30 June 2023 has now been published' and provides a link. According to Rule 2 (The 'MENU VS MEAL' Rule), a short document announcing the publication of a full report, rather than containing the report itself, should be classified as a Report Publication Announcement (RPA). While it mentions the AGM (AGM-R) and the Annual Report (10-K), the primary function of this specific filing is to announce the availability of those items.
2023-10-30 English
Directorate change
Board/Management Information Classification · 99% confidence The document explicitly announces a 'Directorate change' where a director has 'stepped down'. This directly corresponds to the definition of Board/Management Information. The RNS Number (0376R) and the inclusion of contact details for brokers and PR firms confirm it is a formal regulatory announcement, but the core subject matter dictates the specific classification over the general 'RNS' fallback. It is not a general regulatory filing (RNS) because the subject is highly specific (MANG).
2023-10-24 English
Issue of Shares
Share Issue/Capital Change Classification · 98% confidence The document is identified by the RNS Number (3030Q) and contains an announcement dated October 17, 2023, regarding the 'Issue of Shares' to repay a convertible bond. This action directly relates to changes in the company's capital structure and share count. The key event is the issuance of new Ordinary Shares and ADSs to settle debt. This aligns precisely with the definition of 'Share Issue/Capital Change' (SHA). Although it is a regulatory announcement (RNS format), the specific content is about capital structure change, making SHA the most precise classification over the general RNS fallback.
2023-10-17 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.